Trimetrexate Inhibitor

Trimetrexate is an effective competitive inhibitor of bacterial, protozoan, and mammalian dihydrofolate reductase.

Allegra CJ, et al. Trimetrexate for the treatment,of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1987 Oct 15;317(16):978-85.
Fulton B, et al. Trimetrexate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment,of Pneumocystis carinii pneumonia. Drugs. 1995 Apr;49(4):563-76.
Sattler FR, et al. Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/031. J Infect Dis. 1994 Jul;170(1):165-72.

Small volumes of Trimetrexate, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5755660 is an inhibitor targeting Trimetrexate.